Natural human immunoglobulins in cancer immunotherapy

Immunotherapy

Volumn 1, Issue 2, 2009, Pages 241-248

  Vollmers, H Peter ^a   Brändlein, Stephanie ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Apoptosis; Cancer therapy; Innate immunity; Natural antibody

Indexed keywords

BEVACIZUMAB; CETUXIMAB; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; PANITUMUMAB; TRASTUZUMAB;

ANTIBODY RESPONSE; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER RESEARCH; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; REVIEW; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD55; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; APOPTOSIS; COMPLEMENT ACTIVATION; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; GLYCOLIPIDS; HEAT-SHOCK PROTEINS; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN M; NEOPLASMS;

EID: 77953373320     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.2.241     Document Type: Review

References (75)

1. Dalle S, Thieblemont C, Thomas L, Dumontet C: Monoclonal antibodies in clinical oncology. Anticancer Agents Med. Chem. 8, 523-532 (2008).
2. Chari RV: Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41, 98-107 (2008).
3. Larkin JM, Norsworthy PJ, A'Hern RP, Eisen TG, Gore ME, Porter CD: Anti-αGal-dependent complement-mediated cytotoxicity in metastatic melanoma. Melanoma Res. 16, 157-163 (2006).
4. Yan L, Hsu K, Beckman RA: Antibody-based therapy for solid tumors. Cancer J. 14, 178-183 (2008).
5. Widakowich C, de Castro Jr G, de Azambuja E, Dinh P, Awada A: Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12, 1443-1455 (2007).
6. Parham P: Innate immunity: the unsung heroes. Nature 423, 20 (2003).
7. Vollmers HP, Brandlein S: The 'early birds': natural IgM antibodies and immune surveillance. Histol. Histopathol. 20, 927-937 (2005).
8. Cooper MD, Alder MN: The evolution of adaptive immune systems. Cell 124, 815-822 (2006).
9. Medzhitov R: Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145 (2001).
10. Medzhitov R, Janeway CA Jr: Decoding the patterns of self and nonself by the innate immune system. Science 296, 298-300 (2002). ■ Overview about innate immune recognition. (Pubitemid 34303673)
11. Chalifour A, Jeannin P, Gauchat JF et al.: Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers α-defensin production. Blood 104, 1778-1783 (2004).
12. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
13. Kaisho T, Akira S: Toll-like receptor function and signaling. J. Allergy Clin. Immunol. 117, 979-987; quiz 988 (2006).
14. Pasare C, Medzhitov R: Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560, 11-18 (2005).
15. Gay NJ, Gangloff M, Weber AN: Toll-like receptors as molecular switches. Nat. Rev. Immunol. 6, 693-698 (2006).
16. Leulier F, Lemaitre B: Toll-like receptors - taking an evolutionary approach. Nat. Rev. Genet. 9, 165-178 (2008).
17. Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002). ■ First description of M HC-like structures for the recognition of 'self' and 'foreign'.
18. van den Berg TK, van der School CE: Innate immune 'self' recognition: a role for CD47-SIRPα interactions in hematopoietic stem cell transplantation. Trends Immunol. 29, 203-206 (2008).
19. Klee GG: Human anti-mouse antibodies. Arch. Pathol. Lab. Med. 124, 921-923 (2000).
20. + B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol. Today 10, 364-368 (1989). ■ Good summary on the function of polyreactive antibodies produced by a subset of B cells that bear the surface CD5 marker.
21. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, Vollmers HP: Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 63, 7995-8005 (2003). ■■ First detailed paper about the role of innate immunity and especially of natural human antibodies in removal of transformed epithelial cells.
22. Brezinschek HP, Brezinschek RI, Lipsky PE: Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J. Immunol. 155, 190-202 (1995).
23. Adderson EE, Shackelford PG, Quinn A et al.: Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodies and polyspecific antibodies cross-reacting with self antigens. J. Clin. Invest. 91, 2734-2743 (1993).
24. Silverman GJ, Lucas AH: Variable region diversity in human circulating antibodies specific for the capsular polysaccharide of Haemophilus influenzae type b. Preferential usage of two types of VH3 heavy chains. J. Clin. Invest. 88, 911-920 (1991).
25. H genes, but not Vλ genes. J. Clin. Invest. 90, 2197-2208 (1992).
26. Hensel F, Knorr C, Hermann R, Krenn V, Muller-Hermelink HK, Vollmers HP: Mitogenic autoantibodies in Helicobacter pylori-associated stomach cancerogenesis. Int. J. Cancer 81, 229-235 (1999).
27. Hensel F, Hermann R, Schubert C et al.: Characterization of glycosylphosphatidyl-inositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res. 59, 5299-5306 (1999).
28. Hensel F, Brandlein S, Eck M et al.: A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab. Invest. 81, 1097-1108 (2001).
29. Rauschert N, Brandlein S, Holzinger E, Hensel F, Muller-Hermelink HK, Vollmers HP: A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab. Invest. 88, 375-386 (2008).
30. Hakomori S: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56, 5309-5318 (1996).
31. Hakomori S: Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491, 369-402 (2001). ■ Good review about tumor-associated carbohydrate antigens and their impact for the clinic.
32. Vollmers HP, Brandlein S: Tumors: too sweet to remember? Mol. Cancer 6, 78 (2007).
33. Hendershot, LM: The ER function BiP is a master regulator of ER function. Mt Sinai J. Med. 71, 289-297 (2004).
34. Macario AJ, Conway de Macario E: Sick chaperones, cellular stress, and disease. N. Engl. J. Med. 353, 1489-1501 (2005).
35. Delpino A, Piselli P, Vismara D, Vendetti S, Colizzi V: Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin. Mol. Membr. Biol. 15, 21-26 (1998).
36. Ma Y, Hendershot LM: The role of the unfolded protein response in tumour development: friend or foe? Nat. Rev. Cancer 4, 966-977 (2004). (Pubitemid 39626220)
37. Misra UK, Gonzalez-Gronow M, Gawdi G, Pizzo SV: The role of MTJ-1 in cell surface translocation of GRP78, a receptor for α2-macroglobulin-dependent signaling. J. Immunol 174, 2092-2097 (2005).
38. Zhai L, Kita K, Wano C, Wu Y, Sugaya S, Suzuki N: Decreased cell survival and DNA repair capacity after UVC irradiation in association with down-regulation of GRP78/BiP in human RSa cells. Exp. Cell. Res. 305, 244-252 (2005). (Pubitemid 40462538)
39. Li J, Lee AS: Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med. 6, 45-54 (2006).
40. Koumenis C: ER stress, hypoxia tolerance and tumor progression. Curr. Mol. Med. 6, 55-69 (2006).
41. Triantafilou K, Fradelizi D, Wilson K, Triantafilou M: GRP78, a coreceptor for coxsackievirus A9, interacts with major histocompatibility complex class I molecules which mediate virus internalization. J. Virol. 76, 633-643 (2002). (Pubitemid 34033362)
42. Jindadamrongwech S, Thepparit C, Smith DR: Identification of GRP 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2. Arch. Virol. 149, 915-927 (2004).
43. Triantafilou M, Fradelizi D, Triantafilou K: Major histocompatibility class one molecule associates with glucose regulated protein (GRP) 78 on the cell surface. Hum. Immunol. 62, 764-770 (2001).
44. Davidson DJ, Haskell C, Majest S et al.: Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res. 65, 4663-4672 (2005).
45. Fernandez PM, Tabbara SO, Jacobs LK et al.: Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res. Treat. 59, 15-26 (2000).
46. Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS: GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 66, 7849-7853 (2006).
47. Koomagi R, Mattern J, Volm M: Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas. Anticancer Res. 19, 4333-4336 (1999).
48. Uramoto H, Sugio K, Oyama T et al.: Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49, 55-62 (2005).
49. Song MS, Park YK, Lee JH, Park K: Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-ε/ERK/AP-1 signaling cascade. Cancer Res. 61, 8322-8330 (2001).
50. Shuda M, Kondoh N, Imazeki N et al.: Activation of the A TF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J. Hepatol. 38, 605-614 (2003).
51. Lim SO, Park SG, Yoo JH et al.: Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J. Gastroenterol. 11, 2072-2079 (2005).
52. Pootrakul L, Datar RH, Shi SR et al: Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin. Cancer Res. 12, 5987-5993 (2006).
53. Daneshmand S, Quek ML, Lin E et al.: Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum. Pathol. 38, 1547-1552 (2007).
54. Brändlein S, Rauschen N, Rasche N et al.: The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized LDL. Mol. Cancer Ther. 6, (1), 326-333 (2007).
55. Pohle T, Brandlein S, Ruoff N, Muller-Hermelink HK, Vollmers HP: Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res. 64, 3900-3906 (2004). (Pubitemid 38697302)
56. Matsuura E, Hughes GR, Khamashta MA: Oxidation of LDL and its clinical implication. Autoimmun. Rev. 7, 558-566 (2008).
57. Vollmers HP, O'Connor R, Muller J, Kirchner T, Muller-Hermelink HK: SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res. 49, 2471-2476 (1989). (Pubitemid 19125581)
58. Vollmers HP, Eck M, Brändlein S et al.: SC-1, a human antibody for treatment of gastric carcinomas (GCs) - results of a multi-ethnic expression study of the SC-1 antigen. Presented at: Proceedings of the 40th ASCO Annual Meeting. 2004. New Orleans, LA, USA, 5-8 June (2008).
59. Vollmers HP, Dammrich J, Ribbert H, Wozniak E, Muller-Hermelink HK: Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76, 550-558 (1995).
60. Hensel F, Hermann R, Brandlein S et al.: Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab. Invest. 81, 1553-1563 (2001).
61. Vollmers HP, Hensel F, Hermann R et al.: Tumor-specific apoptosis induced by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer. Oncol. Rep. 5, 35-40 (1998).
62. Vollmers HP, Zimmermann U, Krenn V et al.: Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol. Rep. 5, 549-552 (1998).
63. Illert B, Otto C, Vollmers HP, Hensel F, Thiede A, Timmermann W: Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer. Oncol. Rep. 13, 765-770 (2005).
64. Koretz K, Bruderlein S, Henne C, Moller P: Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br. J. Cancer 66, 810-814 (1992).
65. Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME: Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest. 81, 1122-1128 (1988).
66. Caras IW, Davitz MA, Rhee L, Weddell G, Martin DW Jr, Nussenzweig V: Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 325, 545-549 (1987). (Pubitemid 17056740)
67. Hara T, Matsumoto M, Fukumori Y et al.: A monoclonal antibody against human decay-accelerating factor (DAF, CD55), D17, which lacks reactivity with semen-DAF. Immunol. Lett. 37, 145-152 (1993).
68. Lublin DM, Krsek-Staples J, Pangburn MK, Atkinson JP: Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor. J. Immunol. 137, 1629-1635 (1986). (Pubitemid 16014817)
69. Berstad AE, Brandtzaeg P: Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut 42, 522-529 (1998).
70. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149, 129-142 (1996).
71. Spendlove I, Ramage JM, Bradley R, Harris C, Durrant LG: Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol. Immunother. 55, 987-995 (2006).
72. Mikesch JH, Schier K, Roetger A, Simon R, Buerger H, Brandt B: The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell. Oncol. 28, 223-232 (2006).
73. Spendlove I, Li L, Carmichael J, Durrant LG: Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res. 59, 2282-2286 (1999).
74. Durrant LG, Buckley DJ, Robins RA, Spendlove I: 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int. J. Cancer 85, 87-92 (2000).
75. Beutner U, Lorenz U, Illert B et al.: Neoadjuvant therapy of gastric cancer with the human monoclonal IgM antibody SC-1: impact on the immune system. Oncol. Rep. 19, 761-769 (2008).